Brain implant study tests new epilepsy drug
NCT ID NCT07125261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called BHV-7000 in 5 people with epilepsy who have a brain implant (RNS) that records brain activity. The goal was to see if the drug reduces abnormal electrical activity linked to seizures. Participants took the drug for 4 weeks, and their brain recordings were compared to a 90-day period before the drug and a 4-week period after stopping it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yale Comprehensive Epilepsy Center
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the Brain's response to deep brain stimulation?
- Could a night of soft sounds sharpen the epileptic brain?
- Can community hospitals in zambia master severe disease care?
- Can mindfulness rewire the mind to lift depression in epilepsy?
- A break from seizure pills: could less medication mean better living?
- Can invisible electric fields quiet the Brain's seizure signals?